<DOC>
	<DOCNO>NCT01502137</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare steady-state total growth hormone ( GH ) exposure haemodialysis ( HD ) patient match healthy subject .</brief_summary>
	<brief_title>Pharmacokinetics Somatropin Patients With End Stage Renal Disease Receiving Chronic Haemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>PATIENTS : Male female , age equal 18 year undergo chronic haemodialysis Stable adequate haemodialysis treatment three month prior enrolment HEALTHY SUBJECTS : Matching individual patient group : Gender age ( ± 5 year ) Matching individual patient group weight ( dialysis , ±10 % ) Creatinine clearance 80 ml/min Subjects must good health accordance age determine medical history , physical examination , vital sign , ECG ( electrocardiogram ) , routine haematology clinical chemistry Use cuprophane membrane Active malignant disease Diabetes Critical illness define need respiratory circulatory support Known suspect allergy trial product Pregnancy , breast feeding , intention become pregnant fertile woman judge use inadequate contraceptive measure Blood Pressure ( predialysis ) 180/110 Chronic treatment steroid dose 10 mg/day prednisolone ( equivalent ) Treated immunosuppressive agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>